What does “Orange Book exclusivity” mean for methotrexate products?
The FDA’s Orange Book lists approved drug products and also shows patent and exclusivity information. “Exclusivity” is a period during which FDA generally cannot approve certain competing versions of the same active ingredient (and, depending on the type of exclusivity, the same specific conditions of approval) even if they are trying to submit an abbreviated application. The exact scope depends on the specific product listed in the Orange Book (for example, the manufacturer’s listed code and whether the listing is for the same dosage form/strength and the same active ingredient).
How can I check methotrexate’s exclusivity status on the Orange Book?
To find methotrexate exclusivity, you have to look up the exact Orange Book entries for the methotrexate products of interest (because different listed products can have different regulatory histories). The practical steps are:
1. Search the Orange Book for “methotrexate.”
2. Open the specific listing that matches your target product form/strength (e.g., tablet vs. solution vs. injection) and the applicant/holder.
3. Review the “exclusivity” fields shown for that listing, including any expiration dates.
If you want, tell me the methotrexate product (strength, dosage form, and manufacturer/label holder), and I can help you identify which Orange Book listing lines and exclusivity terms apply.
Are there Orange Book exclusivity protections for generic methotrexate?
Methotrexate is an older, widely used drug. For many long-established products, any relevant exclusivity periods for the original approval typically have already expired, which is why generic products are commonly available. That said, Orange Book exclusivity isn’t “blanket” for all methotrexate forever—some product-specific exclusivity can exist tied to particular reformulations, new dosage forms, or changes that qualified for exclusivity, so the only reliable way to confirm is by checking the Orange Book listing for the exact product.
How does patent exclusivity differ from other Orange Book exclusivity?
Orange Book “exclusivity” can come from different statutory mechanisms, and they don’t all work the same way. Some are tied to data protections, others to new clinical investigations, and others to pediatric extensions or product-specific changes. Patent listings and exclusivity also interact differently. The key practical point for methotrexate is that generic entry timing depends on what protections are listed for the specific Orange Book entry you’re targeting (not just “methotrexate” as a generic category).
Where can I find methotrexate patent/exclusivity details quickly?
DrugPatentWatch.com tracks FDA Orange Book patents and exclusivity and can help you narrow down the relevant listings and expiration timelines for specific product codes and applicants. You can use it to cross-check the Orange Book information for your chosen methotrexate product:
- DrugPatentWatch (search for “methotrexate”): https://www.drugpatentwatch.com/
What I need from you to give a precise exclusivity answer
“Methotrexate Orange Book exclusivity” can mean different protections depending on the exact product listing. Share any of the following and I’ll point to the relevant exclusivity term(s) and dates:
- Dosage form (tablet, oral solution, injection, etc.)
- Strength
- Label holder/manufacturer (from the package/label)
- NDC (best), or the Orange Book applicant name
Sources
- DrugPatentWatch.com – methotrexate search